SG11201908296VA - Biomarkers for cancer therapeutics - Google Patents
Biomarkers for cancer therapeuticsInfo
- Publication number
- SG11201908296VA SG11201908296VA SG11201908296VA SG11201908296VA SG 11201908296V A SG11201908296V A SG 11201908296VA SG 11201908296V A SG11201908296V A SG 11201908296VA SG 11201908296V A SG11201908296V A SG 11201908296VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pembrolizumab
- pct
- biomarkers
- low
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT ill~~~~~~~~ 011101010VIIIOH olo Holollm oloiloionomo oimIE (10) International Publication Number WO 2018/201028 Al (51) International Patent Classification: G01N 33/50 (2006.01) A61K 39/395 (2006.01) G01N 33/68 (2006.01) A61K 35/763 (2015.01) G01N 33/574 (2006.01) (21) International Application Number: PCT/US2018/029915 (22) International Filing Date: 27 April 2018 (27.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/491,746 28 April 2017 (28.04.2017) US (71) Applicants: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320 (US). (72) Inventors: GANSERT, Jennifer Lorraine; 337 Long- branch Road, Simi Valley, CA 93065 (US). ANDERSON, Abraham Antonio; 3494 Woodcliff Road, Sherman Oaks, CA 91403 (US). GORSKI, Kevin; 28 Curlew Way, Nova- to, CA 94949 (US). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 1-1 GC N O O 1-1 N 00 O 1-1 N O (74) Agent: JAVIER, Teofilo et al.; Lathrop Gage LLP, 28 State Street, 7th Floor, Boston, MA 02109 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: BIOMARKERS FOR CANCER THERAPEUTICS (57) : Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy com- prising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762491746P | 2017-04-28 | 2017-04-28 | |
PCT/US2018/029915 WO2018201028A1 (en) | 2017-04-28 | 2018-04-27 | Biomarkers for cancer therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908296VA true SG11201908296VA (en) | 2019-10-30 |
Family
ID=62244544
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202110526WA SG10202110526WA (en) | 2017-04-28 | 2018-04-27 | Biomarkers for cancer therapeutics |
SG11201908296V SG11201908296VA (en) | 2017-04-28 | 2018-04-27 | Biomarkers for cancer therapeutics |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202110526WA SG10202110526WA (en) | 2017-04-28 | 2018-04-27 | Biomarkers for cancer therapeutics |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210008135A1 (en) |
EP (2) | EP3615934A1 (en) |
JP (1) | JP2020517715A (en) |
KR (1) | KR20190139225A (en) |
CN (1) | CN110678750A (en) |
AR (1) | AR111432A1 (en) |
AU (1) | AU2018260777A1 (en) |
BR (1) | BR112019022488A2 (en) |
CA (1) | CA3057157A1 (en) |
CL (1) | CL2019002904A1 (en) |
EA (1) | EA201992575A1 (en) |
MX (1) | MX2019012741A (en) |
SG (2) | SG10202110526WA (en) |
TW (1) | TW201900193A (en) |
WO (1) | WO2018201028A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2170959T1 (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
JP2021501150A (en) * | 2017-10-27 | 2021-01-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Compositions and Methods for Treating Liver Cancer |
TW202102543A (en) * | 2019-03-29 | 2021-01-16 | 美商安進公司 | Use of oncolytic viruses in the neoadjuvant therapy of cancer |
US20220018844A1 (en) * | 2020-07-20 | 2022-01-20 | University Of Baltimore, Maryland | Method for Treating a Cancer Based on Inflammatory Subtype Thereof |
CN111766125A (en) * | 2020-07-29 | 2020-10-13 | 广州金域医学检验中心有限公司 | Staining method using fluorescence quenching time difference, automatic staining apparatus, device, and medium |
KR20230061430A (en) * | 2020-08-31 | 2023-05-08 | 브리스톨-마이어스 스큅 컴퍼니 | Cell localization signatures and immunotherapy |
KR102524548B1 (en) * | 2020-11-06 | 2023-04-20 | 사회복지법인 삼성생명공익재단 | Biomarker predictive of responsiveness to an anticancer agent and use thereof |
WO2022271033A1 (en) * | 2021-06-24 | 2022-12-29 | Seljelid, Rolf | Combination of an oncolytic virus, an anti-pd-1 inhibitor and an activator of the innate immune system for use in the treatment of prostate cancer |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
DE3924454A1 (en) | 1989-07-24 | 1991-02-07 | Cornelis P Prof Dr Hollenberg | THE APPLICATION OF DNA AND DNA TECHNOLOGY FOR THE CONSTRUCTION OF NETWORKS FOR USE IN CHIP CONSTRUCTION AND CHIP PRODUCTION (DNA CHIPS) |
EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
ATE173767T1 (en) | 1992-04-03 | 1998-12-15 | Perkin Elmer Corp | SAMPLES COMPOSITION AND METHODS |
US5554501A (en) | 1992-10-29 | 1996-09-10 | Beckman Instruments, Inc. | Biopolymer synthesis using surface activated biaxially oriented polypropylene |
US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
DE4311230C2 (en) | 1993-04-02 | 1996-12-19 | Mannesmann Ag | Non-track-bound vehicle with an electric motor |
US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
US5472672A (en) | 1993-10-22 | 1995-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and method for polymer synthesis using arrays |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US5429807A (en) | 1993-10-28 | 1995-07-04 | Beckman Instruments, Inc. | Method and apparatus for creating biopolymer arrays on a solid support surface |
US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
ATE204290T1 (en) | 1996-11-06 | 2001-09-15 | Sequenom Inc | COMPOSITIONS AND METHODS FOR IMMOBILIZING NUCLEIC ACID ON SOLID SUPPORTS |
CA2268740C (en) | 1996-11-06 | 2010-07-20 | Sequenom, Inc. | High density immobilization of nucleic acids |
US6077674A (en) | 1999-10-27 | 2000-06-20 | Agilent Technologies Inc. | Method of producing oligonucleotide arrays with features of high purity |
PT1252322E (en) | 2000-01-21 | 2005-03-31 | Biovex Ltd | HERPES VIRUS STRETCHES FOR GENE THERAPY |
SI2170959T1 (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
ES2676205T3 (en) | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Stable antibody formulations for the human PD-1 receptor of programmed death and related treatments |
AU2013308595C1 (en) | 2012-08-30 | 2019-01-17 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
US20160304969A1 (en) | 2013-12-17 | 2016-10-20 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
US20160339030A1 (en) * | 2015-05-19 | 2016-11-24 | University Of Maryland, Baltimore | Treatment agents for inhibiting hiv and cancer in hiv infected patients |
MX2017015308A (en) | 2015-05-29 | 2018-07-06 | Merck Sharp & Dohme | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer. |
JP2021501150A (en) * | 2017-10-27 | 2021-01-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Compositions and Methods for Treating Liver Cancer |
-
2018
- 2018-04-27 EP EP18727090.5A patent/EP3615934A1/en not_active Ceased
- 2018-04-27 MX MX2019012741A patent/MX2019012741A/en unknown
- 2018-04-27 SG SG10202110526WA patent/SG10202110526WA/en unknown
- 2018-04-27 AU AU2018260777A patent/AU2018260777A1/en active Pending
- 2018-04-27 EP EP22163106.2A patent/EP4063859A1/en active Pending
- 2018-04-27 CN CN201880026945.7A patent/CN110678750A/en active Pending
- 2018-04-27 WO PCT/US2018/029915 patent/WO2018201028A1/en active Application Filing
- 2018-04-27 AR ARP180101096A patent/AR111432A1/en unknown
- 2018-04-27 TW TW107114398A patent/TW201900193A/en unknown
- 2018-04-27 KR KR1020197030511A patent/KR20190139225A/en not_active Application Discontinuation
- 2018-04-27 SG SG11201908296V patent/SG11201908296VA/en unknown
- 2018-04-27 JP JP2019558526A patent/JP2020517715A/en active Pending
- 2018-04-27 US US16/499,095 patent/US20210008135A1/en active Pending
- 2018-04-27 BR BR112019022488-2A patent/BR112019022488A2/en unknown
- 2018-04-27 CA CA3057157A patent/CA3057157A1/en active Pending
- 2018-04-27 EA EA201992575A patent/EA201992575A1/en unknown
-
2019
- 2019-10-11 CL CL2019002904A patent/CL2019002904A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20190139225A (en) | 2019-12-17 |
CA3057157A1 (en) | 2018-11-01 |
US20210008135A1 (en) | 2021-01-14 |
CL2019002904A1 (en) | 2020-01-17 |
JP2020517715A (en) | 2020-06-18 |
EP4063859A1 (en) | 2022-09-28 |
AU2018260777A1 (en) | 2019-10-17 |
AR111432A1 (en) | 2019-07-10 |
BR112019022488A2 (en) | 2020-06-16 |
EP3615934A1 (en) | 2020-03-04 |
CN110678750A (en) | 2020-01-10 |
SG10202110526WA (en) | 2021-11-29 |
TW201900193A (en) | 2019-01-01 |
EA201992575A1 (en) | 2020-04-13 |
MX2019012741A (en) | 2020-01-21 |
WO2018201028A1 (en) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908296VA (en) | Biomarkers for cancer therapeutics | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201909652WA (en) | Neoantigen identification, manufacture, and use | |
SG11201806861SA (en) | Combination therapy with anti-cd73 antibodies | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201804957VA (en) | Neoantigen identification, manufacture, and use | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201908530QA (en) | Treatment methods | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
SG11201807770RA (en) | Sequence arrangements and sequences for neoepitope presentation | |
SG11201810951RA (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |